CANDEL THERAPEUTICS INC. - COMMON STOCK

5,0400

22-ноября-24 15:44:58

15 мин. задержка

Акции

+0,9050

+21,89%

Сегодняшний диапазон

4,1900 - 5,5700

ISIN

N/A

Источник

NASDAQ

Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

07 ноя 2024 07:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

05 ноя 2024 08:00:32 Источник Nasdaq GlobeNewswire
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

28 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

04 окт 2024 08:00:45 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 авг 2024 07:00:01 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Join Russell 3000® Index

11 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

30 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

23 май 2024 16:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

22 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

20 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

14 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

25 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

11 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

09 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

04 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

28 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

28 мар 2024 07:05:47 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.